Skip to content

Francis Burrows

Francis Burrows

Company: Kura Oncology

Job title: Vice President, Translational Research

Bio:

I am a drug discovery and development scientist with over 25 years’ experience. I earned a PhD in immunology and completed my training in London and Dallas working on antibody-based therapeutics for cancer. Following a brief foray into gene therapy, I have focused on the biology of disease, primarily cancer, and the discovery, characterization and development of small molecule drugs. In 2000 I founded Conforma Therapeutics, led the team that reported the mechanistic basis of Hsp90 inhibition in Nature in 2003 and brought two drugs in to the clinic prior to the acquisition of Conforma by Biogen. At Biogen I was responsible for one clinical, two preclinical and four discovery programs and also initiated efforts to use Hsp90 inhibitors in neurodegenerative and autoimmune conditions. In 2008 I founded Aarden Pharmaceuticals to explore the potential of Protein Tyrosine Phosphatase inhibitors and also took on the role of Head of Oncology Biology at Tragara Pharmaceuticals, where I was responsible for preclinical and translational research on TG01, a COX-2 inhibitor and TG02, a CDK9 inhibitor. I currently hold the position of Vice President of Translational Research at Kura Oncology, a 2014 startup focused on drugs targeted to the Ras-MAPK pathway.

Seminars:

Panel Discussion: Advancing Successful Clinical Translation of RAS Targeted Therapies 2:30 pm

How to translate the promising science and the clear opportunity into safe and effective anti-RAS therapies? Routes for translational success from discovery to clinic: What will be the key factors for generating successful clinical results? What will investors look for in the next few years and what are the major challenges to be overcome in…Read more

day: Day Two

Precision Medicine for HRAS-Mutant Cancer Using Tipifarnib 12:00 pm

HRAS is unique among RAS proteins because it requires farnesylation for activity Tipifarnib is a potent, selective farnesyltransferase activity with a manageable safety profile Tipifarnib is highly active in preclinical models of HRAS-mutant cancer and has recently entered pivotal testing in HRAS-mutant HNSCC patientsRead more

day: Day Two

© Copyright 2018 Hanson Wade | Design and site by Event Engine | Hanson Wade Limited is registered in England & Wales, number 06752216.
Registered Office: Suite A, 6 Honduras Street, London EC1Y 0TH.